ArrayExpress Uploaderarrayexpress_sid2045NUP98-HOXA9192NUP98-HOXA9192NUP98-HOXA972NUP98-HOXA972NUP98-HOXA96NUP98-HOXA96PML-RARA192PML-RARA192PML-RARA72PML-RARA72PML-RARA6PML-RARA6AML1-ETO192AML1-ETO192AML1-ETO72AML1-ETO72AML1-ETO6AML1-ETO6MLL-AF9192MLL-AF9192MLL-AF972MLL-AF972MLL-AF96MLL-AF96empty retroviral vector (control)192empty retroviral vector (control)192empty retroviral vector (control)72empty retroviral vector (control)72empty pTracer-CMV/Bsd vector (control)6empty pTracer-CMV/Bsd vector (control)604Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting different modes of...20805992/profile/8773/arrayexpressuploader230acute myeloid leukemialeukemiamyeloid leukemiapointDec.12, 2014FalseE-GEOD-57194_A-AFFY-44in-vitro-transformation-of-primary-human-cd34-cellhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-57194In Vitro Transformation of Primary Human CD34+ Cells by AML Fusion Oncogenes: Early Gene Expression Profiling Reveals Possible Drug Target in AMLJul.10, 2014Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting different modes of malignant transformation. Here we compare the in vitro effects of representatives of major groups of AML fusion oncogenes on primary human CD34+ cells. For the 3 d and 8 d time points, the oncogenes were retrovirally expressed in primary human CD34+ cells, with cells transduced with empty retroviral vector as controls. As retroviral transduction requires days, for the 6 h time point the oncogenes were expressed from a pTracer-CMV/Bsd plasmid using nucleofection. Cells nucleofected with empty pTracer-CMV/Bsd vector were used as a control.E-GEOD-57194humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-57194/samples/